Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00532038 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.

A Phase 3 study, sponsored by ZARS Pharma.

Terminated
Registry status
Phase 3
Development phase
179
Enrollment target

NCT00532038 is a Phase 3 study that was terminated before completion, run by ZARS Pharma. The registered enrollment target is 179 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00532038, a Phase 3 study, was terminated before completion, sponsored by ZARS Pharma.

TERMINATED
Registry status
Phase 3
Development phase
179 participants
Enrollment target

Study Summary

ThermoProfen is a transdermal ketoprofen patch that is integrated with a long-lasting CHADD (Controlled Heat-Assisted Drug Delivery) unit for the treatment of chronic pain associated with osteoarthritis. This study will evaluate the safety of long-term administration of ThermoProfen™ for the pain associated with osteoarthritis of the knee in adults. The study will be conducted in patients with pain associated with osteoarthritis and who have completed a previous efficacy study of ThermoProfen.

Interventions

  • DRUG ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2007-09
Est. Completion 2008-11
Phase Phase 3

Sponsor

ZARS Pharma

23 total trials

What the Registry Record Tells You About NCT00532038

The ClinicalTrials.gov registry entry for NCT00532038 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System) is the first listed.

NCT00532038 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00532038 about?

NCT00532038 is a clinical study titled "A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.". ThermoProfen is a transdermal ketoprofen patch that is integrated with a long-lasting CHADD (Controlled Heat-Assisted Drug Delivery) unit for the treatment of chronic pain associated with osteoarthritis. This study will evaluate the safety of long-term administration of ThermoProfen™ for the pain as...

What is the current status of trial NCT00532038?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 179 participants. The study started on 2007-09. Estimated completion is 2008-11.

What interventions are being tested in trial NCT00532038?

The interventions under investigation include: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System) (DRUG).

Who is sponsoring clinical trial NCT00532038?

This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.